Leroux-Roels, I.; Bruhwyler, J.; Stergiou, L.; Sumeray, M.; Joye, J.; Maes, C.; Lambert, P.-H.; Leroux-Roels, G.
Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines 2023, 11, 367.
https://doi.org/10.3390/vaccines11020367
AMA Style
Leroux-Roels I, Bruhwyler J, Stergiou L, Sumeray M, Joye J, Maes C, Lambert P-H, Leroux-Roels G.
Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines. 2023; 11(2):367.
https://doi.org/10.3390/vaccines11020367
Chicago/Turabian Style
Leroux-Roels, Isabel, Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert, and Geert Leroux-Roels.
2023. "Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine" Vaccines 11, no. 2: 367.
https://doi.org/10.3390/vaccines11020367
APA Style
Leroux-Roels, I., Bruhwyler, J., Stergiou, L., Sumeray, M., Joye, J., Maes, C., Lambert, P.-H., & Leroux-Roels, G.
(2023). Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines, 11(2), 367.
https://doi.org/10.3390/vaccines11020367